Brief: Aptose Treats First Patient With Continuous Dosing Of New “G3” Formulation Of Luxeptinib
14/11/2022 17:31
Nov 14 (Reuters) - Aptose Biosciences Inc APS.TO :
* APTOSE TREATS FIRST PATIENT WITH CONTINUOUS DOSING OF NEW
“G3”
FORMULATION OF LUXEPTINIB
Source text for Eikon: ID:nGNXnqTG9
Further company coverage: APS.TO
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting